Key facts
- It has raised $127.5M; the latest was Early Stage VC ($97.5M) in Nov 2025.
- Notable investors include Innovation Industrial Technology Transfer, Taya Venture Capital, Himalaya Capital, Abicor Binzel, Axil Capital Partners — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Syncell
- ·The full record, as it builds
Funding rounds
No funding rounds for Syncell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syncell
Developer of a spatial biology system designed to address unattainable complex biological problems. The company's system turns a high-content microscope into a precision photolabeling machine to revolutionize spatial biology and assist in high-content de novo spatial proteomics for the identification of novel proteins for basic research and novel biomarkers for diseases, enabling researchers to harvest all proteins in selected subcellular locations.
- Sector
- Healthcare
- HQ
- Taipei City, Taiwan
- Founded
- 2020
- Website
- syncell.com/
- Ownership
- Privately Held (backing)
Syncell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syncell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syncell in its N-PORT filings yet. We sweep new filings monthly.